Table 1. Clinical characteristics of HNMT patients in LY6K-epitope immunotherapy trials .
| LY6K-LP-specific T-cell responsesa | No. of vaccinations | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Patient ID | Age/Sex | LY6K119–142-LP | LY6K172–191-LP | Histologic subtype | HLA-DRB1 | HLA-DPB1 | |||
| CTR-8379 + CTR-8380 | |||||||||
| Positive/ Total (%) | 10/23 (44%) | 16/23 (70%) | |||||||
| CTR-8379 | Pre-vac. Post-vac. | Pre-vac. Post-vac. | |||||||
| Positive / Total (%) | 2/7 (29%) | 4/13 (31%) | 1/7 (14%) | 8/13 (62%) | |||||
| HNMT10 | 61/M | n.t. | - | n.t. | - | 60 | Squamous Cell Carcinoma | 01:01 / 04:05 | 05:01 / - |
| HNMT20 | 57/F | n.t. | + | n.t. | - | 32 | Squamous Cell Carcinoma | 01:01 / 09:01 | 02:01 / 05:01 |
| HNMT26 | 70/M | n.t. | - | n.t. | + | 24 | Basaloid Squamous Cell Carcinoma | 04:05 / 15:02 | 05:01 / 09:01 |
| HNMT29 | 64/F | n.t. | - | n.t. | + | 16 | Squamous Cell Carcinoma | 09:01 / 14:54 | 03:01 / 05:01 |
| HNMT31 | 69/F | n.t. | + | n.t. | + | 16 | Adenoid Cystic Carcinoma | 01:01 / 11:01 | 02:01 / 04:02 |
| HNMT34 | 65/M | n.t. | - | n.t. | + | 12 | Squamous Cell Carcinoma | 08:03 / 15:02 | 02:01 / 05:01 |
| HNMT35 | 85/F | n.t. | - | n.t. | - | 8 | Squamous Cell Carcinoma | 04:05 / 08:02 | 05:01 / - |
| HNMT39 | 77/M | - | - | - | + | 8 | Adenoid Cystic Carcinoma | 04:06 / 14:54 | 05:01 / 19:01 |
| HNMT40 | 76/M | - | - | - | - | 4 | Squamous Cell Carcinoma | 01:01 / 09:01 | 04:02 / 05:01 |
| HNMT41 | 51/F | + | + | + | + | 4 | Adenoid Cystic Carcinoma | 01:01 / 04:05 | 04:02 / 05:01 |
| HNMT42 | 36/F | + | + | - | + | 4 | Unknown | 01:01 / 08:02 | 04:02 / 05:01 |
| HNMT43 | 50/M | - | - | - | + | 4 | Squamous Cell Carcinoma | 08:02 / 09:01 | 05:01 / - |
| HNMT44 | 55/M | - | n.t. | - | n.t. | 0 | Malignant Melanoma | 01:01 / 13:02 | 04:01 / 09:01 |
| HNMT45 | 82/M | - | - | - | - | 8 | Squamous Cell Carcinoma | 04:03 / 14:03 | 05:01 / - |
| CTR-8380 | Pre-vac. Post-vac. | Pre-vac. Post-vac. | |||||||
| Positive / Total (%) | 0/4 (0%) | 6/8 (75%) | 0/4 (0%) | 8/8 (100%) | |||||
| HNMT102 | 80/F | n.t. | + | n.t. | + | 33 | Squamous Cell Carcinoma | 15:02 / - | 02:01 / 09:01 |
| HNMT103 | 78/F | n.t. | + | n.t. | + | 20 | Mutinous Adenocarcinoma | 04:05 / 15:01 | 02:01 / 05:01 |
| HNMT105 | 65/M | n.t. | + | n.t. | + | 20 | Angiosarcoma | 04:05 / 13:02 | 03:01 / 04:01 |
| HNMT107 | 20/M | n.t. | + | n.t. | + | 20 | Osteosarcoma | 09:01 / - | 02:01 / 02:02 |
| HNMT108 | 41/M | n.t. | - | n.t. | + | 17 | Osteosarcoma | 04:05 / 09:01 | 05:01 / - |
| HNMT109 | 60/F | - | - | - | + | 4 | Squamous Cell Carcinoma | 04:03 / 04:05 | 02:01 / 05:01 |
| HNMT110 | 72/F | - | + | - | + | 8 | Verrucous Carcinoma | 04:10 / 15:02 | 03:01 / 09:01 |
| HNMT111 | 70/F | - | + | - | + | 4 | Squamous Cell Carcinoma | 09:01 / 15:02 | 05:01 / - |
| HNMT112 | 54/M | - | n.t. | - | n.t. | 0 | Squamous Cell Carcinoma | 08:02 / 15:01 | 02:01 / 04:01 |
Summary of the immune responses of helper T (Th) cells reactive to long-peptide (LP) derived from lymphocyte antigen 6 complex locus K (LY6K) from 23 patients enrolled in 2 CTL-epitope peptide-vaccine clinical trials. aLY6K-LP-specific T-cell responses were measured by IFNγ ELISPOT assay. In brief, patient-derived peripheral blood mononuclear cells (PMBCs) were stimulated with the indicated LY6K-LP. Responses were scored as positive when both the mean number of IFNγ spots exceeded 15 and was greater than 2-fold over background. Positive and negative responses are denoted by (+) and (−), respectively. No., Number; CTR, Clinical Trials Registry; vac., vaccination; HNMT, Head and neck malignant tumor; M/F, male/female; LP, long peptide; n.t., not tested